Erythropoietin Claims Monitoring Policy: Implications for Clinical Practice

Erythropoietin Claims Monitoring Policy: Implications for Clinical Practice


Identification: nnj_ma06A7
Issue: March-April 2006
Volume: Vol. 33, No. 2

Standard: $30.00

Description

This article is available to members for free.

Goal: To raise awaremenss of the implications of the new CMS erythropoietin claims policy.

Objectives:

  1. Outline the history of reimbursement for erythropoietin claims for patients with chronic kidney disease.
  2. Summarize 5 provisions included in the CMD reimbursement policy related to erythropoietin for patients with chronic kidney disease.
  3. State the implications for the new CMS policy for erythropoietin claims for professionals involved in the care of those with chronic kidney disease.


Note: This article is supported by an unrestricted educational grant from Amgen. The manuscript has underhone peer review. The information does not necessarily reflect the opinions of ANNA or the sponsor.

Author(s)

Credits

Credits: None available.

You must be logged in and own this product in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content